Adjuvant therapy for colon cancer

Current Oncology Reports

Volumn 7, Issue 3, 2005, Pages 181-185

  Sun, Weijing ^a   Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; TEGAFUR; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; HUMAN; INCIDENCE; INDIVIDUALIZATION; MEDICAL DECISION MAKING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHARMACOGENOMICS; PHYSICIAN; PREDICTION; PROGNOSIS; RISK FACTOR; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; VOMITING;

EID: 18744366689     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0071-4     Document Type: Article

References (36)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics. CA Cancer J Clin 2004, 54:8-29.
2. Eisenberg B, Decosse JJ, Harford E, et al.: Carcinoma or the colon and rectum: the natural history reviewed in 1704 patients. Cancer 1982, 49:1131-1134.
3. National Institute of Health Consensus Con gference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
4. Sun W, Haller D: Chemotherapy for colorectal cancer. Hematol Oncol Clin North Am 2002, 16:969-994.
5. American Joint Committee on Cancer: AJCC Cancer Staging Manual, edn 6. New York: Springer; 2002:113-118.
6. Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003, 10:65-71.
7. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol 2003, 21:2912-2919.
8. Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer. College of american Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:979-994.
9. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al.: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998, 16:427-433.
10. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
11. Buyse M, Zeleniuch-Jaquotte A, Chalmers T, et al.: Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988, 259:3571-3578.
12. Wolmark N, Fisher B, Colangelo L, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30-36.
13. Laurie JA, Moertel CG, Fleming TR, et al.: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 17:1447-1456.
14. Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321-326.
15. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993, 11:1879-1887.
16. Haller DG, Catalano PJ, Macdonald JS, et al.: Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089 [abstract]. Proc ASCO 1998, 17:265a.
17. Andre T, Colin P, Louvet C, et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896-2903.
18. Saini A, Norman AR, Cunningham D, et al.: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003, 88:1859-1865.
19. Saltz LB, Niedzwiecki D, Hollis D, et al.: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803) [abstract]. J Clin Oncol 2004, 22:245s (A3500).
20. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2344-2351.
21. Sargent DJ, Wieand S, Benedetti J, et al.: Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials [abstract]. Proc ASCO 2004, 23:A3502.
22. http://en.sanofi-aventis.com/images/44_24731.pdf Accessed November 14, 2004.
23. Scheithauer W, McKendrick J, Begbie S, et al.: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14:1735-1743.
24. Cassidy J, Scheithauer W, McKendrick J, et al.: Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. J Clin Oncol 2004, 22:247s(A3509).
25. Wolmark N, Wieand S, Lembersky B, et al.: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. J Clin Oncol 2004, 22:247s(A3508).
26. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349-1355.
27. Piedbois P: Introduction, 4th International Conference on Colorectal Cancer in Paris. Semin Oncol 2001, 28 (Suppl 1):1-3.
28. Marsoni S for IMPACT investigators: Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. Semin Oncol 2001, 28 (Suppl 1):14-19.
29. Benson III AB, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
30. Gray RG, Hills BR, Hills R, et al.: QUASAR: A randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients [abstract]. Proc ASCO 2004, 23:A3501.
31. Hikish T, Boni C, Navarro M, et al.: FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): subpopulation data from the MOSAIC trial [abstract]. Proc ASCO 2004, 23:A3619.
32. Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797-1806.
33. Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
34. Iwashyna TJ, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002, 20:3992-3998.
35. Punt CJ, Nagy A, Douillard, et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002, 360:671-677.
36. Fields AL, Keller AM, Schwartzberg L, et al.: Edrecolomab (171A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study [abstract]. Proc ASCO 2002, 21:128a.